Related Experiment Videos
Pharmacokinetics of phenobarbital in childhood
Insights
Phenobarbital elimination is significantly slower in neonates compared to older infants and babies. This prolonged half-life in newborns requires careful consideration for appropriate dosing strategies.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Clinical Pharmacy
Background:
- Phenobarbital is an anticonvulsant medication used in pediatric populations.
- Understanding phenobarbital pharmacokinetics is crucial for safe and effective therapeutic drug monitoring.
- Age-related differences in drug metabolism can significantly impact dosing regimens.
Purpose of the Study:
- To determine the serum levels and pharmacokinetic parameters of phenobarbital in neonates, babies, and infants.
- To compare the elimination half-life and other pharmacokinetic variables across different pediatric age groups.
- To identify potential age-dependent variations in phenobarbital disposition.
Main Methods:
- Serum phenobarbital levels were measured using a gas chromatographic micro-method.
- Phenobarbital was administered intravenously at 5-10 mg/kg body weight.
- Pharmacokinetic parameters were calculated using a two-compartment open model.
Main Results:
- No significant differences were observed in distribution volumes or rate constants (k12, k21) between age groups.
- The elimination half-life of phenobarbital was significantly longer in neonates (118.6 ± 16.1 h) compared to babies (62.9 ± 5.2 h) and infants (68.5 ± 3.2 h).
Conclusions:
- Neonates exhibit a significantly prolonged phenobarbital elimination half-life.
- These findings highlight critical age-related pharmacokinetic differences in phenobarbital.
- Dosage adjustments may be necessary in neonates to prevent potential toxicity due to slower drug clearance.
Abstract:
In 14 neonates 1-4 weeks old, 30 babies aged 1-12 months, and 7 infants of 1-5 years of age, the serum levels of phenobarbital were determined by a gas chromatographic micro-method after intravenous injection of phenobarbital 5-10 mg per kg body weight. It was possible to calculate the pharmacokinetic parameters using a two compartment open model. The distribution volumes within the individual age groups and the rate constants k12 and k21 showed no significant differences, but the elimination half-life was significantly longer in neonates (118.6+/-16.1h) than in babies (62.9+/-5.2h) or infants (68.5+/-3.2h).